Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Acurx Pharmaceuticals ( (ACXP) ) has provided an update.
On March 9, 2026, Acurx Pharmaceuticals’ compensation committee approved voluntary 10% base-salary cuts for its top executives and a 10% reduction in cash retainers for non-employee directors, effective April 1, 2026, while leaving bonus targets and equity incentives unchanged. The measures align leadership pay with market conditions and the company’s operating plan, signaling a focus on cost discipline as Acurx prepares for late-stage clinical development.
Also on March 9, 2026, the company unveiled a new clinical initiative to expand ibezapolstat into recurrent C. difficile infection (rCDI), starting with an open-label pilot trial in up to 20 multiply-recurrent patients to inform a planned Phase 3 registration study. Supported by strong Phase 2 efficacy data, favorable EMA guidance, and existing FDA Fast Track and QIDP status, Acurx aims to position ibezapolstat as a potential single-agent solution for both treatment of CDI and prevention of rCDI, which could materially enhance its competitive standing in a costly, high-unmet-need market.
The most recent analyst rating on (ACXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Acurx Pharmaceuticals stock, see the ACXP Stock Forecast page.
Spark’s Take on ACXP Stock
According to Spark, TipRanks’ AI Analyst, ACXP is a Neutral.
The score is held back primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn) and bearish technicals (price below key moving averages with negative MACD). Earnings-call developments (NASDAQ compliance, IP/scientific progress, and improved cash/net loss) provide some offset, while valuation signals are limited due to negative earnings and no dividend.
To see Spark’s full report on ACXP stock, click here.
More about Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of antibiotics for difficult-to-treat bacterial infections, notably Clostridioides difficile infection (CDI). The company’s lead candidate, ibezapolstat, has shown promising Phase 2 results and is being advanced toward Phase 3 international trials targeting both acute CDI and prevention of recurrent CDI (rCDI).
Average Trading Volume: 52,288
Technical Sentiment Signal: Sell
Current Market Cap: $3.44M
Find detailed analytics on ACXP stock on TipRanks’ Stock Analysis page.